In my opinion, this year’s AACC Conference, one of the major international gatherings of the medical diagnostic industry, was notable for two elements.
First, finally this year, molecular diagnostics seemed to be a mainstream methodology given the prominence and exhibition floorspace dedicated to molecular diagnostic companies.
Representatives of clinical labs with which I spoke, expressed concern about adding the new technology with new demands on lab staff in light of budget pressures. These representatives, however, seemed resigned to the inevitable and curious to learn what’s now available.
Second, the bifurcation of the industry into whales and minnows is increasing. I base this observation on my perceptions versus actual exhibition floorspace statistics.
This year, several small diagnostic companies which have been regular exhibitors in prior years opted to not host a booth or avoid the conference altogether. Giant companies still seem to have the budget while smaller companies weigh every cost. For some, the AACC is simply not essential.
I will continue to attend because the AACC is a great event to see colleagues and meet new friends. As in past years, some of my most rewarding meetings were from chance encounters.
Philadelphia was a good host city. Philadelphians lived up to their reputation, guiding this lost traveler when needed with a generous spirit.
I look forward to following up on conversations and planning for next year in San Diego.